Literature DB >> 21364020

STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.

Zhiming Liu1, Inbal Hazan-Halevy, David M Harris, Ping Li, Alessandra Ferrajoli, Stefan Faderl, Michael J Keating, Zeev Estrov.   

Abstract

NF-κB plays a major role in the pathogenesis of B-cell neoplasms. A broad array of mostly extracellular stimuli has been reported to activate NF-κB, to various degrees, in chronic lymphocytic leukemia (CLL) cells. Because CLL cells harbor high levels of unphosphorylated STAT-3 (USTAT-3) and USTAT-3 was reported to activate NF-κB, we sought to determine whether USTAT-3 activates NF-κB in CLL. Using the electrophoretic mobility shift assay (EMSA), we studied peripheral blood low-density cells from 15 patients with CLL and found that CLL cell nuclear extracts from all the samples bound to an NF-κB DNA probe, suggesting that NF-κB is constitutively activated in CLL. Immunoprecipitation studies showed that STAT-3 bound NF-κB p65, and confocal microscopy studies detected USTAT-3/NF-κB complexes in the nuclei of CLL cells, thereby confirming these findings. Furthermore, infection of CLL cells with retroviral STAT-3-short hairpin RNA attenuated the binding of NF-κB to DNA, as assessed by EMSA, and downregulated mRNA levels of NF-κB-regulated genes, as assessed by quantitative PCR. Taken together, our data suggest that USTAT-3 binds to the NF-κB p50/p65 dimers and that the USTAT-3/NF-κB complexes bind to DNA and activate NF-κB-regulated genes in CLL cells. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21364020      PMCID: PMC4212696          DOI: 10.1158/1541-7786.MCR-10-0559

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  40 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.

Authors:  R R Furman; Z Asgary; J O Mascarenhas; H C Liou; E J Schattner
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

Authors:  Catherine Kern; Jean-Francois Cornuel; Christian Billard; Ruoping Tang; Danielle Rouillard; Virginie Stenou; Thierry Defrance; Florence Ajchenbaum-Cymbalista; Pierre-Yves Simonin; Sophie Feldblum; Jean-Pierre Kolb
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

4.  A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

Authors:  S Cuní; P Pérez-Aciego; G Pérez-Chacón; J A Vargas; A Sánchez; F M Martín-Saavedra; S Ballester; J García-Marco; J Jordá; A Durántez
Journal:  Leukemia       Date:  2004-08       Impact factor: 11.528

5.  Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients.

Authors:  K Schuh; A Avots; H P Tony; E Serfling; C Kneitz
Journal:  Leuk Lymphoma       Date:  1996-11

6.  Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis.

Authors:  Gerd Munzert; Dieter Kirchner; Heike Stobbe; Lothar Bergmann; Roland M Schmid; Hartmut Döhner; Hermann Heimpel
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

7.  Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.

Authors:  Zeev Estrov; Shishir Shishodia; Stefan Faderl; David Harris; Quin Van; Hagop M Kantarjian; Moshe Talpaz; Bharat B Aggarwal
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

8.  Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway.

Authors:  Z Chen; J Hagler; V J Palombella; F Melandri; D Scherer; D Ballard; T Maniatis
Journal:  Genes Dev       Date:  1995-07-01       Impact factor: 11.361

9.  Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation.

Authors:  K Brown; S Gerstberger; L Carlson; G Franzoso; U Siebenlist
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

10.  Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement.

Authors:  Antonia Rodríguez; Nerea Martínez; Francisca I Camacho; Elena Ruíz-Ballesteros; Patrocinio Algara; Juan-Fernando García; Javier Menárguez; Tomás Alvaro; Manuel F Fresno; Fernando Solano; Manuela Mollejo; Carmen Martin; Miguel A Piris
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

View more
  32 in total

1.  Reg3g Promotes Pancreatic Carcinogenesis in a Murine Model of Chronic Pancreatitis.

Authors:  Guoxiao Yin; Jiao Du; Hui Cao; Xiulan Liu; Qianqian Xu; Ming Xiang
Journal:  Dig Dis Sci       Date:  2015-07-17       Impact factor: 3.199

2.  The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.

Authors:  J Claire Godbersen; Leigh Ann Humphries; Olga V Danilova; Peter E Kebbekus; Jennifer R Brown; Alan Eastman; Alexey V Danilov
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

Review 3.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

4.  STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan A Burger; Prithviraj Bose; Phillip A Thompson; Nitin Jain; William G Wierda; Orit Uziel; Michael J Keating; Zeev Estrov
Journal:  J Immunol       Date:  2019-10-23       Impact factor: 5.422

5.  Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Susan O'Brien; Prithviraj Bose; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2017-01-27       Impact factor: 5.852

Review 6.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

7.  Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.

Authors:  Uri Rozovski; Srdana Grgurevic; Carlos Bueso-Ramos; David M Harris; Ping Li; Zhiming Liu; Ji Yuan Wu; Preetesh Jain; William Wierda; Jan Burger; Susan O'Brien; Nitin Jain; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2015-03-02       Impact factor: 5.852

8.  An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.

Authors:  May Daher; Juliana Elisa Hidalgo Lopez; Jasleen K Randhawa; Kausar Jabeen Jabbar; Yue Wei; Naveen Pemmaraju; Gautam Borthakur; Tapan Kadia; Marina Konopleva; Hagop M Kantarjian; Katherine Hearn; Zeev Estrov; Steven Reyes; Carlos E Bueso-Ramos; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2017-06-09       Impact factor: 10.047

9.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

10.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.